major beneficiari lower tax
zoeti appear one biggest pharma beneficiari
tax reform non-gaap tax guidanc vs
origin estimate rais beyond ep
rais pt
rais pt rais pt old
new assign slightli lower multipl
lower tax rate ep
lower tax rate estimate beyond
file today zoeti state expect non-gaap adj effect tax rate
follow tax cut job act enact dec
rais ep estim beyond lower annual
non-gaap tax rate project boost ep
estim annual follow
zoeti subject repatri tax requir remeasur
defer tax asset liabil charg impact adjust
net incom zoeti preliminari review conclud net
reduct us net incom current expect
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base case ep target multipl slight
discount current trade level ntm ep lower
tax rate ep current price-to-earnings premium vs
also roughli line w/ average sinc ipo project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast
base case ep
base case ep
project solid double-digit ep growth driven growth
companion anim livestock project compound-annual-growth-rate revenu growth
ep compound-annual-growth-rate easier us livestock comp global roll-out
new product give us confid project
bear case ep
bear case ep
face lower end-market growth greater competit pressur drive
weak financi result share trade compani miss ep estimate
price-to-earnings multipl contract
rate zoeti ow combin
improv cash flow convers tuck-in
 option drive
ep growth
top-lin growth oper margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
risk achiev price
long-term margin expans fail
new govern regul legisl
impact growth
dollar strength rel foreign
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
